BioMarin Q1 2025 revenue $745M (+15% YoY), GAAP EPS $0.95, reaffirms 2025 guidance

BIOMARIN PHARMACEUTICAL INC

2025-Q1 EPS reported $0.95 revenue$745,145,000

Q1 total revenues $745M (+15% Y/Y); GAAP net income $186M (+109% Y/Y); non-GAAP income $221M (+58% Y/Y).
VOXZOGO revenue $214M (+40% Y/Y) driven by global demand; Enzyme Therapies revenue $484M (+8% Y/Y) led by PALYNZIQ (+22% Y/Y).
GAAP diluted EPS $0.95 (+107% Y/Y); non-GAAP diluted EPS $1.13 (+59% Y/Y). Operating margin expanded 16.4 ppt GAAP, 11.9 ppt non-GAAP.
Reaffirmed full-year 2025 financial guidance; notes immaterial tariff exposure from enacted tariffs.
Pipeline: VOXZOGO pivotal hypochondroplasia study fully enrolled; BMN 333 plan agreed with FDA; PALYNZIQ adolescent study met primary endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.